Relationship of SARS-CoV-2–specific CD4 response to COVID-19 severity and impact of HIV-1 and tuberculosis coinfection
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells are involved in control of coronavirus disease 2019 (COVID-19), but limited knowledge is available on the relationship between antigen-specific T cell response and disease severity. Here, we used flow cytometry to assess the magnitude, function, and phenotype of SARS coronavirus 2-specific (SARS-CoV-2-specific) CD4+ T cells in 95 hospitalized COVID-19 patients, 38 of them being HIV-1 and/or tuberculosis (TB) coinfected, and 38 non-COVID-19 patients. We showed that SARS-CoV-2-specific CD4+ T cell attributes, rather than magnitude, were associated with disease severity, with severe disease being characterized by poor polyfunctional potential, reduced proliferation capacity, and enhanced HLA-DR expression. Moreover, HIV-1 and TB coinfection skewed the SARS-CoV-2 T cell response. HIV-1-mediated CD4+ T cell depletion associated with suboptimal T cell and humoral immune responses to SARS-CoV-2, and a decrease in the polyfunctional capacity of SARS-CoV-2-specific CD4+ T cells was observed in COVID-19 patients with active TB. Our results also revealed that COVID-19 patients displayed reduced frequency of Mycobacterium tuberculosis-specific CD4+ T cells, with possible implications for TB disease progression. These results corroborate the important role of SARS-CoV-2-specific T cells in COVID-19 pathogenesis and support the concept of altered T cell functions in patients with severe disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citationSingle-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790 · cited 1×
“61; Supplemental Figure 2A), as previously reported (8, 15, 42, 43).”
Self-citationRobust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788 · cited 1×
“Moreover, the SARS-CoV-2 response in uninfected controls was characterized by significantly elevated expression of GrB compared to COVID-19 cases (median: 30.6%, [IQR: 5-64.2] vs 4.4%, [IQR: 1.9-9.6], respectively, P = 0.001).”
InfluentialMathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A., Greenplate, A. R., Wu, J. E., Alanio, C., Kuri-Cervantes, L., Pampena, M. B., D’Andrea, K., et al. (2020) · Science · doi:10.1126/science.abc8511 · Cited by 1,509 · cited 1×
“Several publications have reported that severe COVID-19 elicits drastic changes in the overall distribution and phenotypic landscape of circulating T cells, characterized by severe lymphopenia (preferentially affecting CD8 T cells) and widespread T cell activation (4–6).”
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2598-9 · Cited by 1,310
Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0782-6 · Cited by 1,179 · cited 1×
“61; Supplemental Figure 2A), as previously reported (8, 15, 42, 43).”
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
Mateus, J., Grifoni, A., Tarke, A., Sidney, J., Ramirez, S. I., Dan, J. M., Burger, Z. C., Rawlings, S. A., Smith, D. M., Phillips, E., et al. (2020) · Science · doi:10.1126/science.abd3871 · Cited by 1,120
Self-citationA dynamic COVID-19 immune signature includes associations with poor prognosis
Laing, A. G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz, M., McKenzie, D. R., Hayday, T. S., Francos-Quijorna, I., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1038-6 · Cited by 946 · cited 1×
“Both analyses showed that based on the functional and phenotypic traits of SARS-CoV-2 responding CD4 T cells, COVID-19 patients could be discriminated from non-COVID-19 controls.”
Zheng, H.-Y., Zhang, M., Yang, C.-X., Zhang, N., Wang, X.-C., Yang, X.-P., Dong, X.-Q., & Zheng, Y.-T. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0401-3 · Cited by 940
Weiskopf, D., Schmitz, K. S., Raadsen, M. P., Grifoni, A., Okba, N. M. A., Endeman, H., van den Akker, J. P. C., Molenkamp, R., Koopmans, M. P. G., van Gorp, E. C. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd2071 · Cited by 907 · cited 2×
“These cells, likely acquired during previous infections with endemic human coronaviruses, have been identified in 20 to 50% of SARS-CoV-2-unexposed individuals in different populations around the world (8, 10, 15–20).”
Self-citationT cell responses in patients with COVID-19
Chen, Z., & John Wherry, E. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0402-6 · Cited by 797
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
Zhou, R., To, K. K.-W., Wong, Y.-C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.-Y., Lau, T. T.-K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.026 · Cited by 531 · cited 1×
“…COVID-19 severity has been associated with major systemic alterations of the host immune system, including profound lymphopenia, skewed distribution and activation of T cell subpopulations, disruption of the B cell compartment and elevated plasma concentrations of proinflammatory cytokines (3–7).”
Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects
Visca, D., Ong, C. W. M., Tiberi, S., Centis, R., D’Ambrosio, L., Chen, B., Mueller, J., Mueller, P., Duarte, R., Dalcolmo, M., et al. (2021) · Pulmonology · doi:10.1016/j.pulmoe.2020.12.012 · Cited by 328
Cross-reactive memory T cells and herd immunity to SARS-CoV-2
Lipsitch, M., Grad, Y. H., Sette, A., & Crotty, S. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00460-4 · Cited by 260 · cited 2×
“However, while not statistically significant, the proportion of activated Mtb-specific CD4 T cells tended to be higher in COVID-19 co-infected patients compared to the non-COVID-19 group (median: 74 % [IQR: 49-94] vs 57.7% [IQR: 50-77], respectively) (Figure 7E).”
InfluentialSelf-citationSARS–CoV-2–specific T cell responses and correlations with COVID-19 patient predisposition
Sattler, A., Angermair, S., Stockmann, H., Heim, K. M., Khadzhynov, D., Treskatsch, S., Halleck, F., Kreis, M. E., & Kotsch, K. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140965 · Cited by 196 · cited 2×
“Both analyses showed that based on the functional and phenotypic traits of SARS-CoV-2 responding CD4 T cells, COVID-19 patients could be discriminated from non-COVID-19 controls.”
Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?
Juno, J. A., van Bockel, D., Kent, S. J., Kelleher, A. D., Zaunders, J. J., & Munier, C. M. L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00019 · Cited by 195
Neidleman, J., Luo, X., Frouard, J., Xie, G., Gill, G., Stein, E. S., McGregor, M., Ma, T., George, A. F., Kosters, A., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100081 · Cited by 188 · cited 1×
“As previously reported (14, 16, 44), in convalescent COVID-19 patients (n = 9), although the expression of HLA-DR, CD38, and Ki67 in SARS-CoV-2 CD4+ T cells was significantly reduced compared with acute COVID-19 patients (reflecting viral clearance), cells maintained an elevated PD-1 expression and retained their earl…”
Cited by
Dheda, K., Perumal, T., Moultrie, H., Perumal, R., Esmail, A., Scott, A. J., Udwadia, Z., Chang, K. C., Peter, J., Pooran, A., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00092-3 · Cited by 292
The definition of tuberculosis infection based on the spectrum of tuberculosis disease
Migliori, G. B., Ong, C. W. M., Petrone, L., D'Ambrosio, L., Centis, R., & Goletti, D. (2021) · Breathe · doi:10.1183/20734735.0079-2021 · Cited by 166
Cell signaling pathways discovery from multi-modal data
He, C., Simpson, C., Cossentino, I., Zhang, B., Tkachev, S., Eddins, D. J., Kosters, A., Yang, J., Sheth, S., Levy, T., et al. (2025) · doi:10.1101/2025.02.06.636961 · Cited by 3
Metadata
- Authors
- Riou, C., du Bruyn, E., Stek, C., Daroowala, R., Goliath, R. T., Abrahams, F., Said-Hartley, Q., Allwood, B. W., Hsiao, N.-Y., Wilkinson, K. A., Arlehamn, C. S. L., Sette, A., Wasserman, S., & Wilkinson, R. J.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-06-15
- Volume
- 131
- Issue
- 12
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3157371153
- Cited by
- 183
- References
- 21
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.